The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests
BackgroundThe fight against the current coronavirus disease 2019 (COVID-19) pandemic has created a huge demand of biotechnological, pharmaceutical, research and sanitary materials at unprecedented scales. One of the most urgent demands affects the diagnostic tests. The growing need for rapid and acc...
Main Authors: | Laura Williams, Silvia Jurado, Francisco Llorente, Alberto Romualdo, Sara González, Ana Saconne, Isabel Bronchalo, Mercedes Martínez-Cortes, Beatriz Pérez-Gómez, Fernando Ponz, Miguel Ángel Jiménez-Clavero, Pablo Lunello |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Plant Science |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpls.2021.699665/full |
Similar Items
-
An ELISA for antibodies to infectious bronchitis virus based on nucleocapsid protein produced in Escherichia coli
by: D.Y. Zhang, et al.
Published: (2005-08-01) -
Production of spike and nucleocapsid recombinant proteins of porcine epidemic diarrhea virus for antibody detection by ELISA
by: Anchalee Srijangwad, et al.
Published: (2016-02-01) -
IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients
by: Li Yang, et al.
Published: (2021-12-01) -
Comparison of enzyme-linked immunosorbent assay systems using rift valley fever virus nucleocapsid protein and inactivated virus as antigens
by: Fuxun Yu, et al.
Published: (2018-11-01) -
Development of a Nucleocapsid Protein-Based Blocking ELISA for the Detection of Porcine Deltacoronavirus Antibodies
by: Wenlong Wang, et al.
Published: (2022-08-01)